(3D) Ultrasound Imaging Liver and Kidney

NCT ID: NCT03844399

Last Updated: 2025-07-20

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 40 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-10-03
• Study Completion Date: 2027-02-28

Brief Summary

This study is to assess the addition of 3D ultrasound guidance during standard care ablation or biopsies of liver or kidney tumours. 3D ultrasound only differs from conventional 2D ultrasound in that the ultrasound transducer is mounted on a special assembly that moves the transducer in precise, stepped movements while a succession of 2D images are collected by the computer. Special software written specifically for 3D ultrasound precisely aligns these 2D images into a 3-demensional volume , allowing area in question to be viewed in many different planes. 3D ultrasound is a safe, fast, non-invasive imaging procedure. Ultrasound images will be checked against the pre- and post- procedure CT images to make sure the tumours were completely removed or properly targeted during biopsy.

Detailed Description

Images will be acquired by a physician on patients who are undergoing a liver or kidney ablation or biopsy procedure who are well enough to provide consent. Patients will be imaged during the ablation procedure according to the standard of care, and subsequent analysis will commence following the acquisition. The devices being used are all property of the LHSC health network that have been licensed for clinical use through Health Canada. In addition, 3D ultrasound only differs from conventional 2D ultrasound in that the ultrasound transducer is mounted on a special assembly that moves the transducer in precise, stepped movements while a succession of 2D images are collected by the computer. Special software written specifically for 3D ultrasound precisely aligns these 2D images into a 3-dimensional volume, allowing the area in question to be viewed in different planes. The clinical 2D an d3D ultrasound images will be checked against the pre- and post- procedure CT images to make sure the tumours were completely removed.

Conditions

Liver Cancer; Kidney Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Patients

Cancer patients who are scheduled to undergo an ablation or biopsy of a liver or kidney tumour

Ablation

Intervention Type: DEVICE

The medical device will passively record image data during the standard care ablation

Biopsy

Intervention Type: DEVICE

The medical device will passively record image data during the standard care biopsy

Interventions

Ablation

The medical device will passively record image data during the standard care ablation

Intervention Type: DEVICE

Biopsy

The medical device will passively record image data during the standard care biopsy

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• • Patients who are scheduled for standard care liver or kidney ablation or biopsy

Exclusion Criteria

• None

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Western University, Canada

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Victoria Hospital

London, Ontario, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Aaron Fenster

Role: CONTACT

afenster@uwo.ca

5199315777

Facility Contacts

Derek Cool, MD/PhD

Role: primary

5196858500 ext. 54965

Other Identifiers

6319

Identifier Type: -

Identifier Source: org_study_id